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Purpose of the study
First-line HAART with tenofovir DF (TDF) and FTC in piv-
otal trials has been associated with high efficacy and good
tolerability. However, real-life clinical practice often dif-
fers from clinical trials due to co-morbidities, co-infec-
tions, and less intensive clinical monitoring. To evaluate
efficacy and safety of first-line HAART in a day-to-day set-
ting, this Gilead-sponsored non-interventional cohort
was established.
Methods
Between July 2005 and August 2006, 533 HIV-1 infected
antiretroviral-naïve patients from 50 German centres
enrolled in this non-interventional cohort. All patients
were followed every 3 months for 3 years to monitor effi-
cacy (viral load [VL], CD4), tolerability, renal safety, regi-
men changes and resistance profile. All patients received
TDF+FTC as a single tablet (Truvada, TVD) in combina-
tion with either an NNRTI or PI/r as their first antiretrovi-
ral regimen.
Summary of results
As of June 2008, 2 years of therapy have been documented
for 330/533 (62%) patients. At treatment initiation, 81%
were male; median age was 39 years; clinical AIDS diagno-
sis was documented in 22%; 47% started therapy with
CD4 <200 cells/mm3. TVD was combined with an NNRTI
(43%) or a PI/r (57%).
After 24 months, in an As-Treated (AT) analysis, 85%
patients achieved a VL <50 copies/ml (VL <500 copies/ml:
97%), median CD4 count increased from 217 at baseline
to 450 cells/mm3 (IQR: 325–608). Truvada showed a
good safety profile; 76 adverse events (AEs) of any grade
were reported in 66/533 patients (12%); six of these were
judged serious. Fourteen (2.6%) patients discontinued
TVD due to AEs. Renal abnormalities of any grade were
reported in 10 patients (1.9%). Virological failure was
documented in nine patients, of which eight were geno-
typed; M184V/I was detected in three, K65R in two
patients.
Conclusion
During 2 years of follow-up, the overall safety of TVD was
good; renal AEs of any grade were reported in 1.9% of
patients. K65R was detected in two patients. First-line
HAART with TVD plus an NNRTI or PI/r in clinical prac-
tice showed comparable efficacy to that observed in con-
trolled clinical trials.
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